We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast (MED) Q4 Earnings Match Estimates, Sales Surge Y/Y
Read MoreHide Full Article
Medifast, Inc. (MED - Free Report) delivered fourth-quarter 2020 results, wherein both earnings and sales increased year over year and the latter beat the Zacks Consensus Estimate. Strength in OPTAVIA remained a major driver, with average revenue per active earning OPTAVIA coach increasing both year over year and sequentially.
Management said that 2020 was a solid year for the company, with its independent OPTAVIA Coaches attracting and retaining a solid number of new clients. Medifast saw considerable earnings and revenue growth, together with a record level of active earning coaches in 2020, despite the pandemic-led challenges. The company remains committed to making further investments to improve its infrastructure in order to aid growth. Further, Medifast is well placed to encash on the opportunities arising from consumers’ rising inclination toward health and wellness in the United States as well as other parts of the world.
The company posted earnings of $2.36 per share, which came in line with the Zacks Consensus Estimate. Notably, the bottom line surged 42.2% on a year-over-year basis.
Net revenues of $264.9 million advanced 55.3% year over year and beat the Zacks Consensus Estimate of $247 million. Markedly, OPTAVIA-branded products formed 87.2% of consumable units sold in the quarter, up from 83% in the preceding quarter. Incidentally, total active earning OPTAVIA coaches jumped 39% to 44,200.
Further, average revenue per active earning OPTAVIA coach came in at $5,932, up from $5,229 in the same period last year. Certainly, the relevance of the company’s offerings amid an environment where consumers are choosing health and wellness options has been an upside.
Gross profit jumped 55.6% to $199.2 million, while the gross margin increased 10 basis points year over year to 75.2%.
Moving on, SG&A expenses increased from $109.4 million to $161.3 million in the quarter, mainly accountable to escalated OPTAVIA commission costs, stemming from higher OPTAVIA sales, and greater salaries and benefits. This was partly compensated by lower sales and marketing costs. As a percentage of revenues, adjusted SG&A expenses declined 320 basis points to 60.9%.
Income from operations jumped from $18.7 million to $38 million, thanks to higher gross profit, somewhat offset by a rise in SG&A expenses. The operating margin expanded 340 bps to 14.3%. Income from operations was aided by a solid increase in the number of active earning OPTAVIA Coaches, both sequentially and year over year.
Other Financial Updates
The company concluded the quarter with cash, cash equivalents and investment securities of $174.5 million and total shareholders’ equity of $157.2 million. Notably, management did not have any interest-bearing debt on its balance sheet as of Dec 31, 2020.
Concurrently, management announced a quarterly cash dividend of $1.13 per share, which was paid out on Feb 5, 2021. Additionally, it has roughly 2,323,000 shares remaining under its buyback plan. The company anticipates maintaining its quarterly dividend payment practice.
Outlook
Management did not offer any guidance due to the uncertainty surrounding the pandemic. However, the company said that the year-over-year top-line growth trend in January was in line with or even better than the trend witnessed in the fourth quarter. Management further stated that top-line comparisons with the second to fourth quarters of 2020 are likely to be tougher than the one with the first quarter. The company remains on track to support a $2-billion revenue business by 2021-end.
Further, the company said that it plans to close its Medifast direct channel and Medifast branded products, alongside making further investments in the supply chain and technology. Such investments and decisions are likely to elevate costs and affect the company’s operating margin in 2021.
This Zacks Rank #3 (Hold) stock has gained 23.4% in the past three months compared with the industry’s growth of 3.7%.
Celsius Holdings (CELH - Free Report) has a Zacks Rank #2 and its bottom line has outpaced the Zacks Consensus Estimate by a significant margin in the trailing four quarters, on average.
Darling Ingredients (DAR - Free Report) , which currently carries a Zacks Rank #2, has a trailing four-quarter earnings surprise of 26.3%, on average.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year.
Image: Bigstock
Medifast (MED) Q4 Earnings Match Estimates, Sales Surge Y/Y
Medifast, Inc. (MED - Free Report) delivered fourth-quarter 2020 results, wherein both earnings and sales increased year over year and the latter beat the Zacks Consensus Estimate. Strength in OPTAVIA remained a major driver, with average revenue per active earning OPTAVIA coach increasing both year over year and sequentially.
Management said that 2020 was a solid year for the company, with its independent OPTAVIA Coaches attracting and retaining a solid number of new clients. Medifast saw considerable earnings and revenue growth, together with a record level of active earning coaches in 2020, despite the pandemic-led challenges. The company remains committed to making further investments to improve its infrastructure in order to aid growth. Further, Medifast is well placed to encash on the opportunities arising from consumers’ rising inclination toward health and wellness in the United States as well as other parts of the world.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote
Quarterly Highlights
The company posted earnings of $2.36 per share, which came in line with the Zacks Consensus Estimate. Notably, the bottom line surged 42.2% on a year-over-year basis.
Net revenues of $264.9 million advanced 55.3% year over year and beat the Zacks Consensus Estimate of $247 million. Markedly, OPTAVIA-branded products formed 87.2% of consumable units sold in the quarter, up from 83% in the preceding quarter. Incidentally, total active earning OPTAVIA coaches jumped 39% to 44,200.
Further, average revenue per active earning OPTAVIA coach came in at $5,932, up from $5,229 in the same period last year. Certainly, the relevance of the company’s offerings amid an environment where consumers are choosing health and wellness options has been an upside.
Gross profit jumped 55.6% to $199.2 million, while the gross margin increased 10 basis points year over year to 75.2%.
Moving on, SG&A expenses increased from $109.4 million to $161.3 million in the quarter, mainly accountable to escalated OPTAVIA commission costs, stemming from higher OPTAVIA sales, and greater salaries and benefits. This was partly compensated by lower sales and marketing costs. As a percentage of revenues, adjusted SG&A expenses declined 320 basis points to 60.9%.
Income from operations jumped from $18.7 million to $38 million, thanks to higher gross profit, somewhat offset by a rise in SG&A expenses. The operating margin expanded 340 bps to 14.3%. Income from operations was aided by a solid increase in the number of active earning OPTAVIA Coaches, both sequentially and year over year.
Other Financial Updates
The company concluded the quarter with cash, cash equivalents and investment securities of $174.5 million and total shareholders’ equity of $157.2 million. Notably, management did not have any interest-bearing debt on its balance sheet as of Dec 31, 2020.
Concurrently, management announced a quarterly cash dividend of $1.13 per share, which was paid out on Feb 5, 2021. Additionally, it has roughly 2,323,000 shares remaining under its buyback plan. The company anticipates maintaining its quarterly dividend payment practice.
Outlook
Management did not offer any guidance due to the uncertainty surrounding the pandemic. However, the company said that the year-over-year top-line growth trend in January was in line with or even better than the trend witnessed in the fourth quarter. Management further stated that top-line comparisons with the second to fourth quarters of 2020 are likely to be tougher than the one with the first quarter. The company remains on track to support a $2-billion revenue business by 2021-end.
Further, the company said that it plans to close its Medifast direct channel and Medifast branded products, alongside making further investments in the supply chain and technology. Such investments and decisions are likely to elevate costs and affect the company’s operating margin in 2021.
This Zacks Rank #3 (Hold) stock has gained 23.4% in the past three months compared with the industry’s growth of 3.7%.
Check These Solid Food Stocks Now
Hain Celestial (HAIN - Free Report) has a Zacks Rank of 2 (Buy) and a trailing four-quarter earnings surprise of 26.7%, on average. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Celsius Holdings (CELH - Free Report) has a Zacks Rank #2 and its bottom line has outpaced the Zacks Consensus Estimate by a significant margin in the trailing four quarters, on average.
Darling Ingredients (DAR - Free Report) , which currently carries a Zacks Rank #2, has a trailing four-quarter earnings surprise of 26.3%, on average.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>